I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT. Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 2. 2006 Signature:

Patent Docket No. 432722003800

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Wolfgang E. GALLWITZ et al.

Serial No.: 10/575,285

Filing Date: (Int'l) November 2, 2004

For: STIMULATION OF HAIR GROWTH BY GINKGO BILOBA FLAVANOIDS Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literature documents are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 3, 4, and 5 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on May 13, 2005, directed to a counterpart international or foreign application and have not been previously cited.

sd-313683

	his Information Disclosure Statement is submitted:					
	With the application; accordingly, no fee or separate requirements are required.					
Before the mailing of a first Office Action after the filing of a Request for Continue						
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97					
	(e)(1) has been provided.					
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office Action					
	on the merits; accordingly, no fee or separate requirements are required. However, if					
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.					
	After receipt of a first Office Action on the merits but before mailing of a final Office Action					
	or Notice of Allowance.					
	A fee is required. A check in the amount of is enclosed.					
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to					
	this submission in duplicate.					
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is					
	believed to be due.					
	After mailing of a final Office Action or Notice of Allowance, but before payment of the					
	issue fee.					
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the					
	amount of is enclosed.					
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal					
	form (PTO/SB/17 is attached to this submission in duplicate.)					

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 432722003800.

Dated: June 1,2006

Respectfully submitted,

By Katch. Munaceze Kate H. Murashige Registration No.: 29,959

MORRISON & FOERSTER LLP 12531 High Bluff Drive Suite 100

San Diego, California 92130-2040

(858) 720-5112

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/575,285	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	(Int'l) November 2, 2004	
				First Named Inventor	Wolfgang E. GALLWITZ	
				Art Unit	Not Yet Assigned	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	432722003800	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
	1.	US-5,965,157	10-12-1999	Li et al.	
	2.	US-6,261,596	07-17-2001	Li et al.	
	3.	US-6,271,246	08-07-2001	Murad	
	4.	US-6,410,512	06-25-2002	Mundy et al.	
	5.	US-6,465,421	10-15-2002	Duranton et al.	
	6.	US-6,596,266	07-22-2003	Catalfo et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т⁰	

"EXAMINER: Initial If information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional, "See Kinds Codes of USPPO Patent Operational at www.upge.org or MPEP 901 of IA." Enter Offices that issued the document, by he two-hetter code (WPC) Standard S13. "For Patent P

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publish and/or country where publishers.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	7.	DELL'AGLI et al., Planta Med. (2002) 68:76-79				
	8.	International Search Report for PCT/US04/36502, mailed on May 13, 2005, 2 pages	-			
	9.	KIM et al., Skin Pharmacol. (1997) 10:200-205				
	10.	KOBAYASHI et al., Yakugaku Zasshi (1993) 113:718-724	-			
	11.	LEE et al., Life Sci. (1995) 6:551-558				
	12.	ZHONGHUA JIA et al., J. Nat. Prod. (1998) 11:1368-1373	1			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Randall Winston/	Date Considered	11/20/2008
ed-313672		Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.